Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluvastatin + ezetimibe is a combination of two cholesterol-lowering medications used to treat high blood cholesterol and reduce cardiovascular risk. Fluvastatin is an HMG-CoA reductase inhibitor (statin) that works by inhibiting the enzyme responsible for cholesterol synthesis in the liver, thereby lowering LDL ("bad") cholesterol and triglycerides while increasing HDL ("good") cholesterol[1][5][8]. Ezetimibe is a cholesterol absorption inhibitor that blocks the Niemann-Pick C1-like 1 (NPC1L1) protein on intestinal epithelial cells, reducing the absorption of dietary and biliary cholesterol from the small intestine[2][3][6]. The combination targets both endogenous production and exogenous absorption of cholesterol, providing an additive effect in lowering plasma lipid levels. This therapy is primarily indicated for hypercholesterolemia, mixed dyslipidemia, and prevention of cardiovascular events in patients at risk.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluvastatin + ezetimibe.